Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...

Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...

and both trials were placed on clinical hold by the U.S. Food and Drug Administration in February 2024 due to a serious adverse event of liver injury requiring transplant in one patient in the AD ...

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If ...

SpiritMedia.US, a leading international book publishing and marketing company, celebrates the release of The Pyramid Principle by John Vallely with Paul Weissenstein on Tuesday9, 2024. The book shares ...

Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® ...

While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just observed in a study of Keytruda in head and neck cancer.

Merck & Co's FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial found that the cancer immunotherapy improved survival in these patients. Keytruda ...

CAMBRIDGE, MA / ACCESSWIRE / November 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2024. "During the third quarter ...

November updates for Microsoft Advertising, including Copilot enhancements, new video ad features, and improved audience targeting. As holidays near, advertisers launch holiday ad campaigns. Central ...

After hours: 8 November at 18:48 GMT-5 ...

After hours: 8 November at 6:48 pm GMT-5 ...